NCT02322450View on ClinicalTrials.gov

Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

34

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Essential Hypertension
Interventions
DRUG

QGC001

DRUG

Placebo

Trial Locations (4)

35800

Hôpital Arthur Gardiner, Dinard

59037

Hôpital Cardiologique, CHRU de Lille, Lille

69317

Hospices Civils de Lyon - Hôpital de la Croix Rousse, Lyon

75015

Hôpital Européen Georges Pompidou, Paris

All Listed Sponsors
lead

Quantum Genomics SA

INDUSTRY

NCT02322450 - Phase IIa Study of the Product QGC001 Compared With Placebo in Patients With Essential Hypertension | Biotech Hunter | Biotech Hunter